This post was originally published on this site I never knew what I wanted to do with my life. In fact, I’ve always been blatantly envious of people who do. I came from a family of nomadic artists, so I had a feeling I’d never be certain about my career. How could I know exactly…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
First Patients Dosed in Phase 1 Trial Testing ARV-471 in Advanced, ER-Positive Breast Cancer
This post was originally published on this site The first patients have been dosed in a Phase 1 trial evaluating Arvinas‘ experimental therapy ARV-471 for locally-advanced or metastatic ER-positive, HER2-negative breast cancer. Approximately 80% of newly-diagnosed breast cancers produce a protein called an estrogen receptor (ER). In these cancers, the hormone estrogen binds to its…
Rubraca Extends Time to Disease Progression in Recurrent OC, Regardless of Chemo Response, Analysis Shows
This post was originally published on this site Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless of the patients’ response to prior treatment with platinum-based chemotherapy agents. The analysis will be presented at the…
CLR 131 Granted Orphan Drug Status in Europe for Myeloma Treatment
This post was originally published on this site CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug status by the European Commission for the treatment of multiple myeloma, the company announced. The status follows the fast track designation granted in May by the U.S. Food and Drug Administration…
NORD 2019 Rare Disease Summit Set for Oct. 21-22 in Washington, DC
This post was originally published on this site Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told BioNews…
Compass Self Storage Raises $100K for the Leukemia & Lymphoma Society’s Children’s Initiative
This post was originally published on this site Compass Self Storage has raised more than $100,000 this year for the Leukemia & Lymphoma Society (LLS), particularly for its children’s initiative. The $101,618 raised brings to more than $500,000 the amount Compass has donated over the years to LLS, including a local Ohio chapter. Compass is…
Maeton’s OT101 Gets Rare Pediatric Disease Designation for Childhood Brain Tumor
This post was originally published on this site The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Mateon‘s OT101 as a therapy for diffuse intrinsic pontine glioma (DIPG), a difficult-to-treat brain tumor that affects children. The designation is designed to accelerate the development of therapies that can improve the management of…
Mylan Launches Generic Version of Faslodex Injection in the US
This post was originally published on this site The U.S. Food and Drug Administration has approved Mylan‘s generic version of AstraZeneca‘s Faslodex injection to be used for the same breast cancer indications as the original product, the company announced. The approval makes Mylan‘s Fulvestrant injection the third generic version of Faslodex, following the approval of…
Eating Mushrooms May Prevent Prostate Cancer, Japanese Study Suggests
This post was originally published on this site Eating mushrooms frequently — three times a week or more — may have a reduced risk of prostate cancer compared to those eating mushrooms less than once a week, a study of Japanese men found. The association holds true only for men 50 or older, according to…
FDA Grants Abexinostat Fast Track Status for Follicular Lymphoma
This post was originally published on this site Xynomic Pharmaceutical‘s abexinostat has received Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a fourth-line treatment for follicular lymphoma, the company announced in a press release. The decision comes after Xynomic applied for the designation at the beginning of August. The FDA grants…
Spherix Acquires Rights to Anthrax Toxin Altered to Target Ovarian Cancer
This post was originally published on this site Spherix announced that it has closed an exclusive option agreement to license PrAg-PAS, an anthrax-based potential therapy for ovarian cancer developed by scientists at the University of Maryland at Baltimore (UMB). The agreement gives Spherix rights to a patent application, now under consideration by the U.S. Patents Trademark…
Carsgen’s CAR-T Cell Therapy Given Priority Designation in Europe for Multiple Myeloma
This post was originally published on this site CT053, a novel cell-based therapy being developed by Carsgen Therapeutics, was given priority medicines (PRIME) status by the European Medicines Agency (EMA) as a potential treatment of relapsed or refractory multiple myeloma. Early findings from a Phase 1 trial in people with heavily pre-treated disease support the therapy’s…